参考文献/References:
[1]韩雅玲. 冠心病抗血小板治疗的新潮流：降阶治疗[J]. 中华心血管病杂志,2019,10(47),759-761.
[2]Kimura T,Isshiki T,Ogawa H,et al. Randomized,double-blind,dose-finding,phase Ⅱ study of prasugrel in Japanese patients undergoing elective percutaneous coronary intervention[J]. J Atheroscler Thromb,2015,22(6):557-569.
[3]Wiviott SD,Braunwald E,McCabe CH,et al. Prasugrel versus clapidogrel in patients with acute coronary syndromes[J]．N Engl J Med,2007,357(20):2001-2015．
[4]Cannon CP,Harrington RA,James S,et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes(PLATO):a randomised double-blind study[J]. Lancet,2010,375(9711):283-293.
[5]Levine GN,Jeong YH,Goto S,et al. Expert consensus document:World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI[J]. Nat Rev Cardiol,2014,11(10):597-606.
[6]Goto S,Huang CH,Park SJ,et al. Ticagrelor vs. clopidogrel in Japanese,Korean and Taiwanese patients with acute coronary syndrome—Randomized,double-blind,phase Ⅲ PHILO study[J]. Cir J ,2015,79(11):2452-2460.
[7]Neumann FJ,Sousa-Uva M,Ahlsson A,et al. 2018 ESC/EACTS Guidelines on myocardial revascularization[J]. Eur Heart J ,2019,40(2):87-165.
[8]Zettler ME,Peterson ED,McCoy LA,et a1. Switching of adenosine diphosphate receptor inhibitor after hospital discharge among myocardial infarction patients：insights from the Treatment with Adenosine Diphosphate Receptor Inhibitors：Longitudinal Assessment of treatment Patterns and Events after Acute Coronary Syndrome(TRANSLATE-ACS)observational study[J]．Am Heart J,2017,183:62-68．
[9]Steg PG,Huber K,Andreotti F,et al. Bleeding in acute coronary syndromes and percutaneous coronary interventions:position paper by the Working Group on Thrombosis of the European Society of Cardiology[J]. Eur Heart J,2011,32(15):1854-1864.
[10]Levine GN,Bates ER,Bittl JA,et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease:A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines[J]. Am Coll Cardiol,2016,68(10):1082-1115.
[11]Valgimigli M,Bueno H,Byrne RA,et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS:the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology(ESC)and of the European Association for Cardio-Thoracic Surgery (EACTS)[J]. Eur Heart,2018,39(3):213-260.
[12]Mehran R,Rao SV,Bhatt DL,et al. Standardized bleeding definitions for cardiovascular clinical trials:a consensus report from the Bleeding Academic Research Consortium[J]. Circulation,2011,123(23):2736-2747.
[13] Costa F,Vranckx P,Leonardi S,et al. Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation:a pre-specified analysis from the PRODIGY(Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia)trial[J]. Eur Heart J,2015,36(20):1242-1251.
[14]Gilard M,Barragan P,Noryani AAL,et al. 6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin:the randomized,multicenter ITALIC trial[J]. J Am Coll Cardiol,2015,65(8):777-786.
[15]Han YL,Zhang L,Yang LX,et al. A new generation of biodegradable polymer-coated sirolimus-eluting stents for the treatment of coronary artery disease:final 5-year clinical outcomes from the CREATE study[J]. EuroIntervention,2012,8(7):815-822.
[16]Han Y,Xu B,Xu K,et al. Six versus 12 months of dual antiplatelet therapy after implantation of biodegradable polymer sirolimus-eluting stent:randomized substudy of the I-LOVE-IT 2 trial[J]. Circ Cardiovasc Interv,2016,9(2):e003145.
[17]Hahn JY,Song YB,Oh JH,et al. 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome(SMART-DATE):a randomised,open-label,non-inferiority trial[J]. Lancet,2018,391(10127):1274-1284.
[18]Kedhi E,Fabris E,van der Ent M,et al. Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction(DAPT-STEMI):randomised,multicentre,non-inferiority trial[J]. BMJ,2018,363:k3793.
[19]Watanabe H,Domei T,Morimoto T,et al. Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI:the STOPDAPT-2 randomized clinical trial[J]. JAMA,2019,321(24):2414-2427.
[20]CAPRIE Steering Committee. A randomised,blinded,trial of clopidogrel versus aspirin in patients at risk of ischaemic events(CAPRIE).CAPRIE Steering Committee[J]. Lancet,2019,348(9038):1329-1339.
[21]Vranckx P,Valgimigli M,Jüni P,et al. Ticagrelor plus aspirin for 1 month,followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months,followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent:a multicentre,open-label,randomised superiority trial[J]. Lancet,2018,392(10151):940-949.
[22]Hahn JY,Song YB,Oh JH,et al. Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention:the SMART-CHOICE randomized clinical trial[J]. JAMA,2019,321(24):2428-2437.
[23]Mehran R,Baber U,Sharma SK,et al. Ticagrelor with or without aspirin in high-risk patients after PCI[J]. N Engl J Med,2019,381(21):2032-2042.
[24]Bonaca MP,Bhatt DL,Cohen M,et al. Long-term use of ticagrelor in patients with prior myocardial infarction[J]. N Engl J Med,2015,19(372):1791-1800.
[25]Kubica J,Adamski P,Buszko K,et al. Platelet inhibition with standard vs. lower maintenance dose of ticagrelor early after myocardial infarction(ELECTRA):a randomized,open-label,active-controlled pharmacodynamic and pharmacokinetic study[J]. Eur Heart J Cardiovasc Pharmacother,2019,5(3):139-148.
[26]Kim HS,Kang J,Hwang D,et al. Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome(HOST-REDUCE-POLYTECH-ACS):an open-label,multicentre,non-inferiority randomised trial[J]. Lancet,2020,396(10257):1079-1089.
[27]Choi SY,Kim MH,Cho YR,et al. Performance of PRECISE-DAPT score for predicting bleeding complication during dual antiplatelet therapy[J]. Circ Cardiovasc Interv,2018,11(12):e006837.
[28]Yoshikawa Y,Shiomi H,Watanabe H,et al. Validating utility of dual antiplatelet therapy score in a large pooled cohort from 3 Japanese percutaneous coronary intervention studies[J]. Circulation,2018,137(6):551-562.
[29]Ueda P,Jernberg T,James S,et al. External validation of the DAPT score in a nationwide population[J]. Am Coll Cardiol,2018,72(10):1069-1078.
[30]Baber U,Mehran R,Giustino G,et al. Coronary thrombosis and major bleeding after PCI with drug-eluting stents:risk scores from PARIS[J]. Am Coll Cardiol,2016,67(19):2224-2234.
[31]Valgimigli M,Bueno H,Byrne RA,et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS:the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery(EACTS)[J]. Eur Heart J,2018,39(3):213-260.
[32]Schror K,Huber K,Hohlfeld T. Functional testing methods for the antiplatelet effects of aspirin[J]. Biomark Med,2011,5(1):31-42.
[33]Price MJ,Berger PB,Teirstein PS,et al. Standard- vs high dose clopidogrel based on platelet function testing after percutaneous coronary intervention:the GRAVITAS randomized trial[J]. JAMA,2011,305(11):1097-1105.
[34]Trenk D,Stone GW,Gawaz M,et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents:results of the TRIGGER-PCI(Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel)study[J]. J Am Coll Cardiol,2012,59(24):2159-2164.
[35]Deharo P,Pons C,Pankert M,et al. Effectiveness of switching’hyper responders’from Prasugrel to Clopidogrel after acute coronary syndrome:the POBA(Predictor of Bleeding with Antiplatelet drugs)SWITCH study[J]. Int J Cardiol,2013,168(5):5004-5005.
[36]Kazui M,Nishiya Y,Ishizuka T,et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite[J]. Drug Metab Dispos,2010,38(1):92-99.
[37]Mega JL,Close SL,Wiviott SD,et al. Cytochrome p-450 polymorphisms and response to clopidogrel[J]. N Engl J Med,2009,360(4):354-362.
[38]Simon T,Verstuyft C,Mary-Krause M,et al. Genetic determinants of response to clopidogrel and cardiovascular events[J]. N Engl J Med,2009,360(4):363-375.
[39]Naveen LP,Michael EF,Derek S,et al. Effect of genotype-guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention:the TAILOR-PCI randomized clinical trial[J]. JAMA,2020,324(8):761-771.
相似文献/References:
[1]周召锋,吴春阳.急性冠状动脉综合征的抗血小板治疗进展[J].心血管病学进展,2015,(5):646.[doi:10.3969/j.issn.1004-3934.2015.05.032]
ZHOU Zhaofeng,WU Chunyang.Development of Antiplatelet Therapy for Acute Coronary Syndrome[J].Advances in Cardiovascular Diseases,2015,(6):646.[doi:10.3969/j.issn.1004-3934.2015.05.032]
[2]李润土,何泉.光学相干断层成像在急性冠脉综合征介入治疗中的应用[J].心血管病学进展,2019,(6):856.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.005]
LI Runtu,HE Quan.Application of Optical Coherent Tomography in Interventional Treatment of Acute Coronary Syndrome[J].Advances in Cardiovascular Diseases,2019,(6):856.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.005]
[3]郑晓雪 季福绥.急性冠脉综合征患者发生急性肾损伤的临床进展[J].心血管病学进展,2019,(5):713.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.013]
ZHENG Xiaoxue,JI Fusui.Acute Kidney Injury in Patients with Acute Coronary Syndrome[J].Advances in Cardiovascular Diseases,2019,(6):713.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.013]
[4]周小琳 何泉.替格瑞洛在急性冠脉综合征合并慢性肾脏病患者中的应用研究进展[J].心血管病学进展,2019,(5):718.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.014]
ZHOU Xiaolin,HE Quan.Ticagrelor in Acute Coronary Syndrome with Chronic Kidney Disease[J].Advances in Cardiovascular Diseases,2019,(6):718.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.014]
[5]徐俊波 黄刚 蔡琳 刘汉雄 张廷杰.老老年患者抗血小板治疗的循证临床实践[J].心血管病学进展,2019,(8):1123.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.013]
XU Junbo,HUANG Gang,CAI Lin,et al.Evidence-based Antiplatelet Treatment in Very Elderly Patients in Clinical Practice[J].Advances in Cardiovascular Diseases,2019,(6):1123.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.013]
[6]吕俊兴 许海燕.急性冠脉综合征危险评分的研究进展[J].心血管病学进展,2019,(9):1224.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.010]
LU Junxing,XU Haiyan.Risk Scores of Acute Coronary Syndrome[J].Advances in Cardiovascular Diseases,2019,(6):1224.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.010]
[7]吕颖 胡思宁 于波 贾海波.斑块侵蚀发病机制的最新研究进展[J].心血管病学进展,2020,(1):74.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.020]
LU Ying,HU Sining,YU Bo,et al.Pathogenic Mechanisms of Plaque Erosion[J].Advances in Cardiovascular Diseases,2020,(6):74.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.020]
[8]段继坤,林志,杨帆,等.斑块侵蚀引起的急性冠脉综合征的研究新进展[J].心血管病学进展,2020,(3):281.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.016]
DUAN Jikun,LIN Zhi,YANG Fan,et al.Acute Coronary Syndrome Caused by Plaque Erosion[J].Advances in Cardiovascular Diseases,2020,(6):281.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.016]
[9]陈凯磊 胡闻竹 苏冠华.P2Y12抑制剂与癌症风险的相关性研究进展[J].心血管病学进展,2020,(8):798.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.004]
CHEN Kailei,HU Wenzhu,SU Guanhua.Advances in Studies on the Correlation between P2Y12 Inhibitors and Cancer Risk[J].Advances in Cardiovascular Diseases,2020,(6):798.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.004]
[10]肖雨尘 赵仙先 马丽萍.急性冠脉综合征患者提前停服替格瑞洛现象的研究进展[J].心血管病学进展,2020,(11):1120.[doi:10.16806/j.cnki.issn.1004-3934.2020.11.000]
Acute Coronary Syndrome.Premature Ticagrelor Discontinuation in Patients with[J].Advances in Cardiovascular Diseases,2020,(6):1120.[doi:10.16806/j.cnki.issn.1004-3934.2020.11.000]
[11]吕易非 李紫凡 邵褀睿 韩江莉.急性冠脉综合征合并高出血风险患者双联抗血小板治疗研究进展[J].心血管病学进展,2023,(7):577.[doi:10.16806/j.cnki.issn.1004-3934.2023.07.001]
LV Yifei,LI Zifan,SHAO Qirui,et al.Dual Antiplatelet Therapy for Patients with Acute Coronary Syndrome and High Bleeding Risk[J].Advances in Cardiovascular Diseases,2023,(6):577.[doi:10.16806/j.cnki.issn.1004-3934.2023.07.001]
[12]努尔古丽·玉苏普 古力尼尕尔·麦麦提吐尔孙 陈清杰 艾尔肯·阿吉.急性冠脉综合征合并糖尿病患者P2Y12受体拮抗剂治疗进展[J].心血管病学进展,2023,(7):593.[doi:10.16806/j.cnki.issn.1004-3934.2023.07.005]
Nurgul·Yusup,Gulinigar·Mamattursun,CHEN Qingjie,et al.P2Y12 Receptor Antagonist Therapy in A cute Coronary Syndrome with Diabetes[J].Advances in Cardiovascular Diseases,2023,(6):593.[doi:10.16806/j.cnki.issn.1004-3934.2023.07.005]